Phosphoinositide 3-kinase inhibitor
A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a class of medical drug that functions by inhibiting one or more of the phosphoinositide 3-kinase enzymes, which are part of the PI3K/AKT/mTOR pathway, an important signalling pathway for many cellular functions such as growth control, metabolism and translation initiation. Within this pathway there are many components, inhibition of which may result in tumor suppression. These anti-cancer drugs are examples of targeted therapy.
There are a number of different classes and isoforms of PI3Ks.Class 1 PI3Ks have a catalytic subunit known as p110, with four types (isoforms) – p110 alpha, p110 beta, p110 gamma and p110 delta. The inhibitors being studied inhibit one or more isoforms of the class I PI3Ks.
They are being actively investigated for treatment of various cancers.
They are also being considered for inflammatory respiratory disease.
Inhibiting different p110 isoforms can have different effects. e.g. PTEN-negative tumors may be more sensitive to p110β inhibitors.
In/starting phase II clinical trials:
With phase I results announced :
In early stage clinical trials
Others
...
Wikipedia